M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 54.32 USD 4.74% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

MoonLake Immunotherapeutics
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MoonLake Immunotherapeutics
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
Cash from Financing Activities
$479.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash from Financing Activities
$73.9m
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Financing Activities
CHf40.1m
CAGR 3-Years
51%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Financing Activities
$354.1m
CAGR 3-Years
-19%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Financing Activities
-CHf1.2m
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Xlife Sciences AG
SIX:XLS
Cash from Financing Activities
CHf828.6k
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MoonLake Immunotherapeutics
Glance View

Market Cap
3.4B USD
Industry
N/A

MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

MLTX Intrinsic Value
7.72 USD
Overvaluation 86%
Intrinsic Value
Price
M

See Also

What is MoonLake Immunotherapeutics's Cash from Financing Activities?
Cash from Financing Activities
479.7m USD

Based on the financial report for Dec 31, 2023, MoonLake Immunotherapeutics's Cash from Financing Activities amounts to 479.7m USD.

What is MoonLake Immunotherapeutics's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
301%

Over the last year, the Cash from Financing Activities growth was 301%.

Back to Top